Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dapagliflozin and Sildenafil in Heart Failure with Secondary Pulmonary Hypertension
NCT06778330Completed
- Sponsor
- Fayoum University
- Start
- Jan 2025
- Primary completion
- Aug 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised trial of sildenafil in secondary pulmonary hypertension (2 arms), sponsored by Fayoum University. Primary endpoints: Change in ejection fraction at 12 weeks and Change in systolic pulmonary artery pressure at 12 weeks. Started Jan 2025; status: completed.
02
Drugs
sildenafil
03
Conditions
secondary pulmonary hypertension
Beyond the preview
Go deeper on NCT06778330.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06778330.